Lindahl advised Nanologica on the offering. Nanologica finalized a rights issuance, which was resolved by the board of directors on 29 August 2024 and approved by...
You must be a Standard 1 Year member to access this content.
Lindahl advised Senzime AB on the deal. Senzime AB (publ) announced a rights issue which was resolved by the board of directors on 23 January 2023 and...
You must be a Standard 1 Year member to access this content.
Lindahl advised Senzime AB on the deal. Senzime AB announced the company’s list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market. Trading...
You must be a Standard 1 Year member to access this content.
Lindahl has assisted Emplicure AB on the deal. Emplicure AB announced the listing of the company’s shares on Nasdaq First North Growth Market. In connection with the...
You must be a Standard 1 Year member to access this content.
Lindahl assisted Q-linea on the deal. Q-linea AB (publ), a company listed on Nasdaq Stockholm that develops and delivers innovative solutions for the diagnosis of infectious...
You must be a Standard 1 Year member to access this content.
Lindahl assisted Q-linea on the deal. Q-linea AB (publ), a company listed on Nasdaq Stockholm that develops and delivers innovative solutions for the diagnosis of infectious...
You must be a Standard 1 Year member to access this content.
